Pramipexole in treatment-resistant depression: an extended follow-up
about
The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disordersPharmacological Approaches for Treatment-resistant Bipolar DisorderEmerging targets for antidepressant therapiesNovel targets for antidepressant therapiesCurrent and emerging therapies for the management of bipolar disordersOptions for Pharmacological Treatment of Refractory Bipolar DepressionPostpartum and depression status are associated with lower [[¹¹C]raclopride BP(ND) in reproductive-age womenWhy do some promising brain-stimulation devices fail the next steps of clinical development?The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatmentBinding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457.Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression.Treatment strategies to improve and sustain remission in major depressive disorder.Advances in the Management of Treatment-Resistant DepressionNeuroendocrine predictors of the evolution of depression.Augmentation and combination strategies for depression.Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness.Antidepressants and sexual dysfunction.Emerging treatments for major depression.Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study.Dopaminergic influences on emotional decision making in euthymic bipolar patientsRecognition and management of Parkinson's disease during the premotor (prodromal) phase.Emerging drugs for major depressive disorder.Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder.Therapeutic armamentarium for treating depression.Dopamine agonist-responsive depression.Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.Dopaminergic mechanisms in memory consolidation and antidepressant reversal of a chronic mild stress-induced cognitive impairment`.Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain.Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain.Imaging the role of inflammation in mood and anxiety-related disorders.Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs).Efficacy of Low-dose Pramipexole Augmentation in the Treatment of Refractory Psychotic Depression Complicated with Tardive Dyskinesia: A Case ReportDepressive Disorders: Major Depressive Disorder and Persistent Depressive Disorder
P2860
Q22241325-5F16EDC8-7FEB-483D-BD91-0034AC003EBFQ26783002-618829F4-E0F5-47B0-8EC6-D118F1A9398BQ28247614-4EF87502-9D1C-488B-9277-6E5EB28C26AAQ28648254-292D9B9E-99DA-4E45-BAD0-64A8B3A0718BQ28686902-322147FF-D954-42A2-AADB-7A9DD5AE2C62Q29395337-CA276D52-A2B7-4858-8E1B-C9CDE8B77426Q30419672-22696BED-4A7E-4080-8502-B34CFD814EC9Q33519672-F7F5F757-BEF7-4981-9E74-562CE1914EFBQ33593061-447C7767-E2D4-4AD0-8545-083EDFFA0C96Q33847160-679F80C7-C636-45DF-95AA-54F6F3F5F748Q34654574-2C2F9017-8453-4285-8833-BEB863F5490BQ35237047-6B3A0CFE-7082-4E58-B73F-937E0EC891DFQ35580600-9148110F-593B-4C11-9F52-6798B712A865Q36255135-A632C141-5D27-46EF-8C2D-071DA9454EE1Q36462566-6A7BE073-9CDA-45F2-A5B5-3F87294BF86DQ36498715-A9E2A98C-0558-4C05-8302-5918AF2EB5FBQ36646241-729F9A23-BFFC-4841-ADC7-941600B0EFF6Q36730674-C8A61AB5-6FF8-4786-A654-C3913385C7D6Q36902050-0E076040-7D86-4F6C-9590-A4DD7001855FQ37409558-3F7DC607-6CB4-458D-A096-507F27BDC227Q37507968-525D37C5-4AF0-4EDF-BD53-9CAECC0274DBQ37564562-FB967065-3948-42A3-BBE3-5455C216DC70Q37734565-B730F1E5-0052-4A7E-863F-F267C3B09BA2Q37777008-CB4AF75D-9A81-4B99-8A1B-27742A21584CQ38443130-45335CEE-46AB-4B01-A9B6-A874F48AF53FQ38915253-57815160-9AB6-4652-AE0E-CD6446B356E2Q41310518-EA46A62D-7D93-412C-976D-E9512B4C3FDCQ42592621-4B453A36-00B0-45DB-8FB4-982637FE1AC5Q46439905-D32928A8-8074-4BC7-A85E-021DBB1D0FB2Q47305318-0DD097A3-F6AC-482F-8341-CB830CEE8819Q55421497-DE1521CE-3E3A-4465-B62D-1D802D648E67Q55969862-344A0DA4-D448-43A6-BA41-E2B2EA3D71A3Q57703141-1D9E6666-93E1-4B12-9C48-2321D9EE9C44
P2860
Pramipexole in treatment-resistant depression: an extended follow-up
description
2004 nî lūn-bûn
@nan
2004 թուականին հրատարակուած գիտական յօդուած
@hyw
2004 թվականին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Pramipexole in treatment-resistant depression: an extended follow-up
@ast
Pramipexole in treatment-resistant depression: an extended follow-up
@en
Pramipexole in treatment-resistant depression: an extended follow-up
@nl
type
label
Pramipexole in treatment-resistant depression: an extended follow-up
@ast
Pramipexole in treatment-resistant depression: an extended follow-up
@en
Pramipexole in treatment-resistant depression: an extended follow-up
@nl
prefLabel
Pramipexole in treatment-resistant depression: an extended follow-up
@ast
Pramipexole in treatment-resistant depression: an extended follow-up
@en
Pramipexole in treatment-resistant depression: an extended follow-up
@nl
P2093
P356
P1476
Pramipexole in treatment-resistant depression: an extended follow-up
@en
P2093
Alfredo Gemignani
Federico Soldani
Giovanni Battista Cassano
Giulia Battistini
Lorenzo Lattanzi
Paolo Cassano
Serena Navari
P2860
P356
10.1002/DA.20038
P407
P577
2004-01-01T00:00:00Z